Back to Authors

Pokorney, Sean D

Mayo Clinic

From the Division of Cardiology, Duke University Medical Center (S.D.P., E.D.P., S.M.A.-K.), Duke Clinical Research Institute (S.D.P., A.S.H., L.H.C., E.D.P., H.R.A.-K., K.J.A., S.M.A.-K.), Durham, NC; Division of Cardiology, Northwestern University Medica

Citations 2

Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration’s Approach for Its Product Labeling
Shrader, Peter, Thomas, Laine , Fonarow, Gregg C. , Kowey, Peter R. , Singer, Daniel E. , Ansell, Jack , Go, Alan S. , Piccini, Jonathan P. , Pokorney, Sean D, Pokorney, Sean D. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D.

Circulation | October 10, 2016 | Volume: 134 | Issue: 15 | Pages: 1122-1124

10.1161/circulationaha.116.024333 Get It

Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients
Hellkamp, Anne S., Curtis, Lesley H. , Hammill, Stephen C., Masoudi, Frederick A. , Bhatt, Deepak L. , Al‐Khalidi, Hussein R. , Heidenreich, Paul A. , Anstrom, Kevin J. , Fonarow, Gregg C. , Pokorney, Sean D, Yancy, Clyde W. , Al-Khalidi, Hussein R, Al-Khatib, Sana M, Pokorney, Sean D. , Peterson, Eric D. , Al‐Khatib, Sana M. , Bhatt, Deepak L

Circulation: Arrhythmia and Electrophysiology | December 13, 2014 | Volume: 8 | Issue: 1 | Pages: 145-151

10.1161/circep.114.001878 Get It

Background— Racial and ethnic minorities are under-represented in clinical trials of primary prevention implantable cardioverter-defibrillators (ICDs). This analysis investigates the association between primary prevention ICDs and mortality among Medicare, racial/ethnic minority patients. Methods and Results— Data from Get With The Guidelines-Heart Failure Registry and National Cardiovascular Data Registry’s ICD Registry were used to perform an adjusted comparative effectiveness analysis of primary prevention ICDs in Medicare, racial/ethnic minority patients (nonwhite race or Hispanic ethnicity). Mortality data were obtained from the Medicare denominator file. The relationship of ICD with survival was compared between minority and white non-Hispanic patients. Our analysis included 852 minority patients, 426 ICD and 426 matched non-ICD patients, and 2070 white non-Hispanic patients (1035 ICD and 1035 matched non-ICD patients). Median follow-up was 3.1 years. Median age was 73 years, and median ejection fraction was 23%. Adjusted 3-year mortality rates for minority ICD and non-ICD patients were 44.9% (95% confidence interval [CI], 44.2%–45.7%) and 54.3% (95% CI, 53.4%–55.1%), respectively (adjusted hazard ratio, 0.79; 95% CI, 0.63–0.98; P =0.034). White non-Hispanic patients receiving an ICD had lower adjusted 3-year mortality rates of 47.8% (95% CI, 47.3%–48.3%) compared with 57.3% (95% CI, 56.8%–57.9%) for those with no ICD (adjusted hazard ratio, 0.75; 95% CI, 0.67%–0.83%; P <0.0001). There was no significant interaction between race/ethnicity and lower mortality risk with ICD ( P =0.70). Conclusions— Primary prevention ICDs are associated with lower mortality in nonwhite and Hispanic patients, similar to that seen in white, non-Hispanic patients. These data support a similar approach to ICD patient selection, regardless of race or ethnicity.